PDS Biotechnology Corp EDGE Balance Sheet

Pds biotechnology corp (EDGE)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Dec'14
ASSETS
Current assets:
Cash and cash equivalents
21,037	12,161	17,406	21,734	26,592	103	36,814	45,978	74,996	88,067	97,307	108,714	95,590	106,398	112,784	111,022	119,942	130,189	52,879	13,728
Prepaid expenses and other
2,879	2,308	726	1,098	1,313	18	247	580	917	986	326	636	699	954	359	793	841	1,081	339	212
Deferred issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,378	1,405
Total current assets
23,917	14,470	18,133	22,832	27,906	122	37,062	46,559	75,913	89,054	97,633	109,351	96,290	107,353	113,144	111,815	120,784	131,270	55,597	15,347
Property and equipment, net
17	21	26	368	412	29	468	510	552	3,423	3,462	3,491	3,465	3,418	3,291	3,461	2,838	2,766	2,781	1,443
IPR&D asset
-	-	1,223	1,223	1,223	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-to-use assets
-	-	-	1,233	1,347	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
-	-	0	145	155	12	142	142	142	142	142	142	142	142	142	142	142	55	104	55
Total assets
23,934	14,491	19,383	25,804	31,045	164	37,673	47,212	76,609	92,621	101,239	112,985	99,898	110,914	116,579	115,419	123,766	134,092	58,483	16,846
LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES
Current liabilities:
Accounts payable
2,556	1,197	1,488	1,853	2,665	1,307	590	1,723	2,957	4,369	2,964	4,350	2,527	3,471	1,963	2,854	2,882	2,584	2,644	2,045
Accrued expenses
1,220	1,097	1,296	638	446	601	917	6,024	8,472	5,422	3,282	4,154	3,638	3,213	2,290	1,519	1,358	3,734	3,590	1,582
Restructuring reserve
269	498	858	1,283	1,948	0	5,179	6,121	-	0	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities- short term
-	-	-	492	477	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short term debt
-	-	-	-	-	-	0	0	20,900	3,075	5,454	3,086	579	0	0	2,389	2,329	2,271	2,214	265
Total current liabilities
4,046	2,793	3,643	4,267	5,538	1,909	6,688	13,869	32,330	12,866	11,701	11,590	6,745	6,684	4,253	6,763	6,570	8,589	8,450	3,893
Noncurrent liability:
Warranty liability
-	-	-	-	-	291	-	-	-	-	-	-	-	-	-	-	-	-	3,726	1,671
Deferred tax liability
-	-	157	157	157	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities- long term
-	-	-	774	902	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible promissory notes payable
-	-	0	0	0	30	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities
4,046	2,793	-	-	-	2,230	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long term debt
-	-	-	-	-	-	0	0	0	17,382	14,883	17,127	14,505	14,953	14,817	1,899	2,472	3,025	3,686	2,327
STOCKHOLDERS' EQUITY
Preferred stock, 5,000,000 shares authorized at September 30, 2019 and December 31, 2018, 0 outstanding
-	-	0	0	0	-	0	0	0	0	0	0	0	0	-	-	-	0	-	-
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2020 and December 31, 2019, 15,350,445 shares and 5,281,237 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
5	1	1	1	1	1	10	10	10	10	10	10	9	9	9	9	9	9	0	0
Additional paid-in capital
52,805	40,633	39,414	38,686	38,642	19,871	220,705	218,798	217,057	214,309	212,688	211,021	191,895	190,341	-	-	-	-	-	-
Additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	189,058	187,546	186,137	184,721	3,550	1,984
Accumulated deficit
-32,923	-28,937	-23,833	-18,082	-14,196	-21,939	-189,731	-185,466	-172,788	-151,948	-138,044	-126,763	-113,258	-101,074	-91,559	-80,800	-71,424	-62,253	-54,195	-29,818
Total stockholders' equity
19,887	11,697	15,582	20,605	24,447	-2,066	30,984	33,342	44,279	62,371	74,653	84,268	78,646	89,276	97,508	106,756	114,722	122,477	-50,643	-27,833
Total liabilities and stockholders' equity
23,934	14,491	19,383	25,804	31,045	164	37,673	47,212	76,609	92,621	101,239	112,985	99,898	110,914	116,579	115,419	123,766	134,092	58,483	16,846